AI Insight
The ALIGN phase 3 trial investigated atrasentan in patients with IgA nephropathy over 2.5 years in a randomized, double-blind, placebo-controlled study. Results showed that atrasentan significantly reduced proteinuria and preserved kidney function compared to placebo. The treatment was well tolerated and demonstrated effectiveness both in patients taking SGLT2 inhibitors and those not taking them.
Why it matters
IgA nephropathy is the most common primary glomerulonephritis worldwide and a leading cause of kidney failure. This trial provides evidence for a new therapeutic option that may slow disease progression and delay the need for dialysis or transplantation in affected patients.
Atrasentan reduced proteinuria and preserved kidney function after 2·5 years. This effect was present with or without concomitant SGLT2 inhibitor use. Atrasentan was well tolerated.